Dr. Nagla Abdel Karim (@NaglaAKarimMD) ranks #25 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 9 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: LAURA, NeoADAURA, IMforte. CMS Open Payments lists $22,530 in 2025 general payments.
At a Glance
- 4 posts naming a trial in 2026
- 5 trials discussed by name
- Lung Cancer: US #25 · 9 physicians engaged
- Leading physician voice: #2 of 6 physicians on LAURA; #2 of 3 physicians on NeoADAURA
- Presented at WCLC 2026 in 2026
- CMS Open Payments lists $22,530 in 2025 general payments.
This Month
What Dr. Nagla Abdel Karim has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Dr. Nagla Abdel Karim
Physicians who reposted Dr. Nagla Abdel Karim’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #25 | — | 9 | 12 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Dr. Nagla Abdel Karim presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · Educational presentationOligometastatic mini learning modulesSource: @NaglaAKarimMD on X ↗
Trials Dr. Nagla Abdel Karim Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| LAURA | 1 | #2 of 6 | Oct 10, 2026 |
| NeoADAURA | 1 | #2 of 3 | Oct 10, 2026 |
| IMforte | 1 | #8 of 12 | Oct 10, 2026 |
| MAVERICK (SWOG S1827) | 1 | #14 of 33 | Sep 12, 2026 |
| HARMONi-6 | 1 | #34 of 74 | May 31, 2026 |
Dr. Nagla Abdel Karim on LAURA
Debating whether to use NEOADAURA vs LAURA @JSabari @JuliaRotow which one should we choose? @Joshua_Reuss @StephenVLiu @chulkimMD #DCLung26 https://t.co/jIVkSkxLvC
Dr. Nagla Abdel Karim on NeoADAURA
Debating whether to use NEOADAURA vs LAURA @JSabari @JuliaRotow which one should we choose? @Joshua_Reuss @StephenVLiu @chulkimMD #DCLung26 https://t.co/jIVkSkxLvC
Dr. Nagla Abdel Karim on IMforte
SCLC Panel; Adding my overview: Extensive Stage SCLC first Line therapy: consider current options; Imforte vs clinical trials, consider adding trilaciclib & awaiting Tarla maintenance data especially if Brain Metastasis #DCLung26 https://t.co/lhPkDTiWOm
Dr. Nagla Abdel Karim on MAVERICK (SWOG S1827)
We are so excited and looking forward to the presidential session especially the MAVERICK data in SCLC @IASLC #WCLC26 @lungoncdoc @LauraAlderMD @drshieldsmd @CharuAggarwalMD @oncodaily @OncoAlert @SWOG https://t.co/MElaf1GWPd
Dr. Nagla Abdel Karim on HARMONi-6
The story of VEGF inhibitors in squamous cell NSCLC is very interesting! Ivonescimab in HARMONi-6 study discussion happening now! @juliebrahmer #ASCO26 https://t.co/jbpQhFooMq
Dr. Nagla Abdel Karim’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
I can’t wait to learn about the results of #S1827 in the presidential session on the first day of #WCLC2026 @IASLC @SWOG #PCI in Limited Stage SCLC & Extensive Stage SCLC Benefits, neurotoxicity, Early detection of lesions, role of MRI & SRS all are important questions. https://t.co/WGCEXlTLi1
Join us at #WCLC2026 for our Join us for the IASLC-EMRO Forum session on Saturday 2-4 PM Local Time. Thank you @IASLC & all colleagues. https://t.co/Sj3oJ2cE2c
In between running to catch up on our sessions & meetings! Thankful for our oncology family #WCLC26 @OncoAlert @oncodaily @lungoncdoc @drshieldsmd @LauraAlderMD @LealTiciana @SalmaJabbour1 @AmyDolnick1 https://t.co/cSHm2ptCI0
Ivonescimab + Chemo showed significant improvement in OS and manageable toxicity profile in advanced squamous NSCLC as first line treatment mOS 27.89 months #ASCO26 https://t.co/kTmdUc0AY2
Arriving to Beautiful Seoul & could not resist walking right away to #Starfield_Library & walking with @CharuAggarwalMD Thank you @IASLC for making the world come together #WCLC26 https://t.co/8n7YlfwMR1
Industry Payments
CMS Open Payments · 2025 general payments
$22,530 across 33 payments